On June 3, 2019 Nordic Nanovector ASA (OSE: NANO) reported that the European Patent Organisation (EPO) has granted the company’s European Patent covering the use of Betalutin or Humalutin in combination with anti-CD20 antibodies for the treatment of non-Hodgkin’s lymphoma (NHL) (Press release, Nordic Nanovector, JUN 3, 2019, View Source [SID1234553449]). The same patent has also been issued in Japan, China, Australia, Hong Kong, Israel, Russia and Singapore while the patent is pending in USA, Brazil, Canada, Indonesia, India, Korea, Mexico, New Zealand, Philippines, Ukraine and South Africa.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This patent is a result of Nordic Nanovector’s continued focus on securing intellectual property rights on its pipeline of novel CD37-targeting drug candidates.

Patents covering Betalutin and Humalutin, as well as their medical applications have already been granted in Europe, USA, Canada, China, Hong Kong, Australia, Indonesia, Israel, Japan, Korea, Mexico, New Zealand, Philippines, Russia, Singapore, Ukraine and South Africa. India, Brazil and Thailand are expected to be granted soon.

Finally, two newer patent applications related to Betalutin’s clinical applications and combination with other drugs have also been filed. The latest application has been made public on the 31 May under WO/2019/101789.